Robin Shah, Executive Chairman at Thyme Companies, shared an update from Thyme Companies, on LinkedIn, adding:
“Today, I couldn’t be more excited about the launch of Thyme Therapeutics, the first new venture from Thyme Companies.
One month ago when we announced Thyme Companies, we discussed wanting to disrupt more parts of the oncology ecosystem that would improve the experience for patients and providers. Thyme Therapeutics will unlock that vision for drug affordability.
We’re living in an incredible chapter where cancer medicines have the power to extend and transform people’s lives in ways that have never been done before. But those medicines only work if they are sustainable for patients, providers, and health insurance plans.
That’s where Thyme Therapeutics comes in. Thyme Therapeutics was built with the ambition to lower the financial burden on patients and families navigating a cancer journey, bringing high-quality, low-cost biosimilars to market in partnership with oncology providers and manufacturers to improve access and affordability.”
Quoting Thyme Companies:
“This is a defining moment for cancer care. Medicines have the opportunity to extend and transform patients’ lives in ways we’ve never seen. But a treatment only works if it reaches the patient who needs it.
Today we’re launching a company to tackle that challenge.
Introducing Thyme Therapeutics, the newest addition to the Thyme Companies family of businesses.
Thyme Therapeutics is building a more sustainable model for cancer medicine: an oncology biosimilars model designed to bring lower-cost medicines to market, with more stable, durable pricing over time. Our goal is to help ensure that more of the value biosimilars create reaches patients and the healthcare system.”
This also can be interesting:
The Hidden Burden of Cancer Hospitalization
